In May, the organization surveyed 27 cancer centers about their supply levels of cisplatin and carboplatin — two staple chemotherapies used for multiple cancers — and 25 said they were experiencing shortages. Four months later, the scope of the monthslong shortages is slightly better.
The latest survey found that 72% of the centers were short on carboplatin and 59% continue to report a cisplatin shortage. Overall, 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.
In the previous survey, 93% of cancer centers were facing a carboplatin shortage and 70% “lacked a steady supply of cisplatin,” the NCCN said.
In mid-September, the White House declared the nation’s cisplatin shortage was nearly over after the U.S. imported lots from China and domestic drugmakers ramped up production. Around the same time, a Novartis prostate cancer drug, Pluvicto (lutetium lu-177 vipivotide tetraxetan) injection, returned to normal supply levels after falling into shortage in March.
A few other cancer drugs have recently joined the pile of ongoing shortages, though, including vinblastine — a lymphoma therapy that does not have an equal alternative.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
